Digital Partnering | September 16–17, 2025
10 Sept - Asia Bio Day 2 - SGT / Singapore
Over the past decade, APAC has emerged as a global biotech powerhouse, driven by investment growth, innovation hubs, and evolving regulatory frameworks. This keynote panel brings together industry leaders to discuss how the region must navigate geopolitical shifts, scale innovation, and solidify its position in the global biotech ecosystem.
- How are geopolitical and economic trends shaping the future of APAC biotech?
- What are some of the investment patterns driving biotech growth across the region?
- Understanding how regional collaboration can accelerate biotech commercialization and innovation?
- Can APAC take the lead in next-generation therapeutics and cutting-edge biotech technologies?
Session Themes: Strategy / Collaboration / Investment / Innovation / Global Expansion
Across Asia, NewCos are emerging as a powerful tool for biotech innovation—unlocking capital, enabling focused execution, and driving cross-border dealmaking. Whether through spin-outs, asset-centric models, or joint ventures, NewCos are reshaping how companies scale and go global. This esteemed panel explores the evolving art of the deal: what’s working, what’s next, and how pharma, VCs, and startups are collaborating to build the next generation of biotech success stories.
- What are NewCos and how are biotechs using them to de-risk R&D, accelerate speed to market, and pursue global ambitions?
- What deal structures—M&A, licensing, spin-outs, JVs—are defining the next wave of biotech growth in Asia?
- How do you balance strategic control, scientific focus, and capital efficiency in today’s deals?
- Trends in pharma-Biotech and VC-Biotech partnerships that are shaping Asia’s role in the global ecosystem.
Session Themes: Investment Trends / Dealmaking / Strategic Partnerships
As APAC emerges as a leader in next-generation therapies—such as live biotherapeutics and cell & gene therapies—it faces challenges in regulatory alignment, infrastructure, and partnership models. This session explores how biotech companies and regional stakeholders can align strategies to bring these therapies to market faster and more effectively. Panelists will also discuss overcoming regulatory fragmentation, addressing manufacturing bottlenecks, and the strategic value of cross-border and public-private partnerships.
- How feasible is regulatory harmonization for novel therapeutics in APAC—and who should drive it?
- What infrastructure is critical to support manufacturing and clinical development ifor emerging therapies?
- What types of partnerships—cross-border, Public Private Partnership, academic—are proving most impactful in bringing these therapies to patients?
Session Themes: Regulatory Strategy / Strategic Partnerships / Infrastructure
In an uncertain funding climate, biotech companies must refine their business case and narrative to attract investment. This session brings together investors and seasoned executives to discuss how capital is flowing across the region, what sets a pitch apart, and how to how to thrive in an increasingly competitive environment.
- What do today’s investors really want from biotech CEOs in APAC?
- How can early-stage companies stand out in a crowded, capital-constrained market?
- What role do platform technologies, delivery innovations, and team credibility play in funding decisions?
- How are funding priorities evolving—regionally and globally—and what trends should founders watch for?
Session Themes: Strategy / Investment / Dealmaking / Capital Markets
As Asia solidifies its place in the global biotech ecosystem, the region is becoming a hotbed for cross-border M&A, licensing, and strategic partnerships. But behind every headline-making deal lies a complex interplay of cultural nuance, market dynamics, and talent dynamics. In this dynamic closing panel, biotech, pharma, and investment leaders will share how to navigate the art and science of dealmaking in Asia—from trust-building and negotiation styles to talent alignment, valuation trends, and long-term value creation. Expect a candid, high-energy conversation full of practical insight and deal-tested wisdom.
- How do cultural dynamics influence deal structures and timelines in key APAC markets?
- What makes a biotech company in Asia an attractive partner or acquisition target for global players—and vice versa?
- Are valuations in APAC catching up with global markets, or does a gap persist?
- How can companies overcome regulatory, operational, cultural, and talent-related challenges when executing and integrating cross-border deals?
Session Themes: Dealmaking / Strategic Partnerships / Cultural Intelligence / Global Strategy